Twitter | Search | |
Healio Hepatology
Hepatology news and meeting coverage powered by SLACK Incorporated, a leading publisher of medical specialty newspapers, journals & books.
4,266
Tweets
386
Following
4,623
Followers
Tweets
Healio Hepatology Jul 19
Concomitant chronic and were significantly more likely to lead to advanced and -related outcomes including mortality compared with chronic alone.
Reply Retweet Like
Healio Hepatology Jul 18
The has granted $3.42 million in research and career development awards to 29 researchers and clinicians to conduct research and undergo advanced training.
Reply Retweet Like
Healio Hepatology Jul 18
InSphero AG announced the launch of 3D InSight Human Liver Disease Discovery Platform, a 3D cell technology for development and safety testing of and .
Reply Retweet Like
Healio Hepatology Jul 17
Harvoni joins other direct-acting antivirals in demonstrating safety and high efficacy in younger pediatric patients with chronic , specifically those aged 3 years to younger than 6 years.
Reply Retweet Like
Healio Hepatology Jul 17
Coalition of Medication-Assisted Treatment Providers and Advocates of New York State joins the University of Buffalo in ongoing study of in treatment programs to provide care for substance users.
Reply Retweet Like
Healio Hepatology Jul 16
Living donor showed multiple superior outcomes compared with deceased donor liver transplantation, including longer survival and shorter lengths of hospital stay.
Reply Retweet Like
Healio Hepatology Jul 15
Healio presents the following recent reports on , including an expert editorial on lifestyle intervention, recent pipeline updates, and the outcomes of using multiple noninvasive test to best identify NASH-related .
Reply Retweet Like
Healio Hepatology Jul 15
Researchers found that population density and water balance were key factors influencing the occurrence of E outbreaks, according to a study published in .
Reply Retweet Like
Healio Hepatology Jul 11
Mirum Pharmaceuticals dosed the first patient in a phase 3 trial of , its lead drug candidate for the treatment of patients with progressive familial intrahepatic cholestasis .
Reply Retweet Like
Healio Hepatology Jul 10
VCTE outperformed APRI and Fibrosis-4 index as a noninvasive biomarker for advanced in patients with B and coinfection.
Reply Retweet Like
Healio Hepatology Jul 10
Combination of three noninvasive tests maintained acceptable performance in identifying advanced due to while reducing the rate of indeterminate results.
Reply Retweet Like
Healio Hepatology Jul 9
demonstrated 100% SVR and a safety profile consistent with adult patients in adolescent patients aged 12 years to 17 years with , according results from part one of the DORA study.
Reply Retweet Like
Healio Hepatology Jul 5
DILIsym Services released NAFLDsym Version 2A, a quantitative systems pharmacology modeling software designed to support the development of treatments for and .
Reply Retweet Like
Healio Hepatology Jun 28
Cara Therapeutics announced the initiation of a phase 2 trial of oral Korsuva for the treatment of in patients with hepatic impairment due to primary biliary cholangitis.
Reply Retweet Like
Healio Hepatology Jun 26
Zydus Cadila completes patient enrollment in its phase 2 trial of Lipaglyn (saroglitazar magnesium) for the treatment of and .
Reply Retweet Like
Healio Hepatology Jun 25
Treatment with and ribavirin was well-tolerated and highly effective in children aged 3 years to less than 12 years in pediatric patients with genotype 2 or genotype 3.
Reply Retweet Like
Healio Hepatology Jun 24
Results from a phase 3 study of for unresectable revealed that the drug showed a trend toward improvement in overall survival but did not meet significance for its primary endpoint.
Reply Retweet Like
Healio Hepatology Jun 24
While most countries in the EU and the European Economic Area have reported a decline in acute rates over the last decade, reports showed an increase in cases of chronic , according to data from the .
Reply Retweet Like
Healio Hepatology Jun 21
Poor oral health correlated with an increased risk for hepatobiliary , including , according to an analysis of data from the UK Biobank cohort.
Reply Retweet Like
Healio Hepatology Jun 20
Medivir released interim results from a phase 1a study of MIV-818 for the treatment of advanced that showed selective effect signal on liver cancer tissue.
Reply Retweet Like